前列腺癌是我国男性比较常见的泌尿系统恶性肿瘤，随着我国人口的老龄化以及人们生活方式的改变，其发病率和死亡率逐渐增高，已严重威胁人们的健康，其发病率在2030年有望增加1倍。多参数磁共振成像（Mp-MRI）是一种将解剖学磁共振成像（MRI）与一个或多个功能性MR成像序列相结合的全新的成像模态。Mp-MRI的传统作用仅限于前列腺癌的分期，但随着物理学以及医学的不断发展，多样的成像序列也被不断开发并应用于临床。目前Mp-MRI序列包括常规T1、T2加权成像和功能MRI，如动态对比增强磁共振成像（DCE-MRI）、弥散加权成像（DWI）、磁共振波谱（MRS）和磁共振光谱成像（MRSI）等，其作用已扩展到临床诊疗的各个阶段，包括前列腺癌的检测、定位、侵袭性评估以及肿瘤分期、治疗疗效的评价，提供了评估肿瘤生物学行为的非侵入性解决方案。本文就Mp-MRI在前列腺癌临床诊疗中的应用以及其优势与不足进行综述，展望Mp-MRI在前列腺疾病诊疗中的新定位。
Abstract
Prostate cancer is a common malignant tumor in men. With the aging of the population and the changes of peoples lifestyle, its incidence rate and mortality rate have been increasing. It has seriously threatened peoples health, its incidence rate is expected to double in 2030. Multiparameter magnetic resonance imaging (Mp-MRI) is a new imaging modality that combines anatomical MR imaging (MRI) with one or more functional MR imaging sequences. The traditional role of Mp-MRI is limited to PCa staging, but with the continuous development of physics and medicine, a variety of imaging sequences have been developed and applied in clinical. At present, Mp-MRI sequence includes conventional T1, T2 weighted imaging and functional MRI, such as dynamic contrast-enhanced MRI (DCE-MRI), diffusion-weighted imaging (DWI), magnetic resonance spectroscopy (MRS) and magnetic resonance spectroscopy (MRSI), etc. Its role has been extended to all stages of clinical diagnosis and treatment, including detection, localization, invasive evaluation, tumor stage, the evaluation of therapeutic effect, provides a non-invasive solution to evaluate the biological behavior of tumor. This paper reviews the application of Mp-MRI in the clinical diagnosis and treatment of prostate cancer, its advantages and disadvantages, and looks forward to the new location of multiparameter Mp-MRI in the diagnosis and treatment of prostate diseases.
关键词
前列腺癌 /
肿瘤 /
多参数磁共振成像
Key words
Prostate cancer /
Tumor /
Multiparametric-MRI
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
1.Maddams J, Utley M, Moller H. Projections of cancer prevalence in the United Kingdom. Br J Cancer.2012；107(7)：1195-1202.
2.Fütterer Jurgen J. Multiparametric MRI in the detection of clinically significant prostate cancer. Korean J Radiol. 2017； 18(4)：597-606.
3.Zhu K, Qin Z, Xue J, et al. Comparison of prostate cancer detection rates between magnetic resonance imaging-targeted biopsy and transrectal ultrasound-guided biopsy according to prostate imaging reporting and data system in patients with PSA ≥4ng/mL：a systematic review and meta-analysis. Transl Androl Urol. 2019；8(6)：741-753.
4.De CN, Lombardo R, Nacchia A, et al. Repeat prostate-specific antigen test before prostate biopsy：a 20% decrease in prostate specific antigen values is associated with a reduced risk of cancer and particularly of high-grade cancer. Bju Int. 2018；122(1)：83-88.
5.Cristel G, Esposito A, Damascelli A, et al. Can DCE-MRI reduce the number of PI-RADS v.2 false positive findings? Role of quantitative pharmacokinetic parameters in prostate lesions characterization. Eur J Radiol.2019； 118：51-57.
6.Wang X, Qian Y, Liu B, et al. High-b value diffusion-weighted MRI for the detection of prostate cancer at 3 T. Eur J Radiol .2014；69(11)：1165-1170.
7.AR, M J TB, NC, et al. Signal intensity of high B-value diffusion-weighted imaging for the detection of prostate cancer.J Biomed Phys Eng.2019； 9(4)：453-458.
8.Chin JL, Billia M, Relle J, et al. Magnetic resonance imaging-guided transurethral ultrasound ablation of prostate tissue in patients with localized prostate cancer：a prospective phase 1 vcinical trial. Eur Urol.2015；70(1)：1-9.
9.Si Y, Liu RB. Diagnostic performance of monoexponential DWI versus diffusion kurtosis imaging in prostate cancer：a systematic review and Meta-analysis. Am J Roentgenol. 2018；211(2)：358-368.
10.Ning P, Shi D, Sonn GA, et al. The impact of computed high b-value images on the diagnostic accuracy of DWI for prostate cancer：a receiver operating characteristics analysis. Sci Rep.2018； 8(1)：1-9.
11.Ma XZ, Lv K, Sheng JL, et al. Application evaluation of DCE-MRI combined with quantitative analysis of DWI for the diagnosis of prostate cancer. Oncol Lett.2019； 17(3)：3077-3084.
12.Janesya, Sutedjo, 陈慧铀, et al. 磁共振波谱成像在前列腺癌中的应用. 磁共振成像.2015；6(1)：71-75.
13.Zhao N, Ma C, Ye X et al. The feasibility of b-value maps based on threshold DWI for detection of breast cancer：a case-control STROBE compliant study. Medicine (Baltimore). 2019；98(44)：e17640.
14.Gautam KA, Singh AN, Srivastav AN, et al. Angiogenesis in prostate cancer and benign prostatic hyperplasia assessed by VEGF and CD-34 IHC：a comparative clinico-pathological study. Afr J Urol.2018；24(2)：98-103.
15.Ciolina M, Caruso D, Santis DD, et al. Dynamic contrast-enhanced magnetic resonance imaging in locally advanced rectal cancer：role of perfusion parameters in the assessment of response to treatment. La Radiol Med. 2018；124(5)：331-338.
16.Wang B, Gao J, Zhang Q, et al. Investigating the equivalent performance of biparametric compared to multiparametric MRI in detection of clinically significant prostate cancer. Abdom Radiol (NY).2020；45(2)：547-555.
17.Zhang TH, Hu CH, Chen JX, et al. Differentiation diagnosis of hypo-intense T2 area in unilateral peripheral zone of prostate using magnetic resonance spectroscopy (MRS)：prostate carcinoma versus prostatitis. Med Sci Monit.2017；23：3837-3843.
18.Palermo G, Totaro A, Sacco E, et al. High intensity focused ultrasound as first line salvage therapy in prostate cancer local relapse after radical prostatectomy：4-year follow-up outcomes. Minerva Urol Nefrol.2017； 69(1)：93-100.
19.Larbi A, Omoumi P, Pasoglou V, et al. Whole-body MRI to assess bone involvement in prostate cancer and multiple myeloma：comparison of the diagnostic accuracies of the T1, short inversion recovery (STIR), and high b-values diffusion-weighted imaging (DWI) sequences. Eur Radiol. 2019； 29(8)：4503-4513.
20.Perera M, Krishnananthan N, Lindner U, et al. An update on focal therapy for prostate cancer. Nat Rev Urol.2016； 13(11)：641-653.
21.Hadjipavlou M, Eragat M, Kenny C, et al. Effect of augmented antimicrobial prophylaxis and rectal swab culture-guided targeted prophylaxis on the risk of sepsis following transrectal prostate biopsy. Eur Urol Focus.2018； 175(2)：95-101.
22.Papadopoulos I, Phillips J, Evans R, et al. Evaluation of diffusion weighted imaging in the context of multi-parametric MRI of the prostate in the assessment of suspected low volume prostatic carcinoma. Magn Reson Imaging. 2018；47：131-136.
23.Ouzzane A, Helfrich O, Le Nobin J. Understanding the pathological implications of MRI：application to focal therapy planning. Curr Opin Urol.2015；25(3)：198-204.
24.Kongnyuy M, Halpern DM, Liu CC, et al. 3-T multiparametric MRI characteristics of prostate cancer patients suspicious for biochemical recurrence after primary focal cryosurgery (hemiablation). Int Urol Nephrpl.2017；49(11)：1947-1954.
25.Moore CM, Robertson NL, Arsanious N, et al. Image-guided prostate biopsy using magnetic resonance imaging-derived targets： a systematic review. Eur Urol.2013；63(1)：125-140.
26.Panebianco V, Barchetti F, Sciarra A, et al. Prostate cancer recurrence after radical prostatectomy：the role of 3-T diffusion imaging in multi-parametric magnetic resonance imaging. Eur Radiol.2013；23(6)：1745-1752.
27.Couago F, Sancho G, Catalá V, et al. Magnetic resonance imaging for prostate cancer before radical and salvage radiotherapy：What radiation oncologists need to know.World J Clin Oncol.2017；8(4)：305-319.
28.Park SY, Oh YT, Jung DC, et al. Diffusion-weighted imaging (DWI) predicts upgrading of Gleason score in biopsy-proven low-grade prostate cancers. Bju Inter.2017；119(1)：57-66.
PDF(941 KB)
